Pharsight

Breo Ellipta patents expiration

BREO ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44874 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(6 months ago)

US7439393 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(1 year, 7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7776895 GLAXO GRP LTD Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
Sep, 2022

(1 year, 17 days ago)

US7439393

(Pediatric)

GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
Nov, 2025

(2 years from now)

US8511304 GLAXO GRP LTD Medicament dispenser
Jun, 2027

(3 years from now)

US9333310 GLAXO GRP LTD Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXO GRP LTD Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

US8511304

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Dec, 2027

(4 years from now)

US8161968 GLAXO GRP LTD Medicament dispenser
Feb, 2028

(4 years from now)

US9333310

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Apr, 2028

(4 years from now)

US8113199

(Pediatric)

GLAXO GRP LTD Counter for use with a medicament dispenser
Apr, 2028

(4 years from now)

US8161968

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Aug, 2028

(4 years from now)

US11116721 GLAXO GRP LTD Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
Feb, 2029

(5 years from now)

US11116721

(Pediatric)

GLAXO GRP LTD Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
Aug, 2029

(5 years from now)

US8534281 GLAXO GRP LTD Manifold for use in medicament dispenser
Mar, 2030

(6 years from now)

US8534281

(Pediatric)

GLAXO GRP LTD Manifold for use in medicament dispenser
Sep, 2030

(6 years from now)

US8746242 GLAXO GRP LTD Medicament dispenser
Oct, 2030

(7 years from now)

US8746242

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Apr, 2031

(7 years from now)

Breo Ellipta is owned by Glaxo Grp Ltd.

Breo Ellipta contains Fluticasone Furoate; Vilanterol Trifenatate.

Breo Ellipta has a total of 18 drug patents out of which 2 drug patents have expired.

Expired drug patents of Breo Ellipta are:

  • US7776895
  • USRE44874

Breo Ellipta was authorised for market use on 10 May, 2013.

Breo Ellipta is available in powder;inhalation dosage forms.

Breo Ellipta can be used as indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; for the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations, indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including bronchitis and/or emphysema; indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; indicated for the once-daily treatment of asthma in patients 18 years and older; indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations, indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations; indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older, indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations.

The generics of Breo Ellipta are possible to be released after 11 April, 2031.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) May 13, 2026
New Strength (NS) May 13, 2026

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; Long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bron...

Dosage: POWDER;INHALATION

More Information on Dosage

BREO ELLIPTA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic